BOSTON– AI Proteins has appointed Dr. James Bowman, Ph.D., as its first Chief Technology Officer. Bowman, a founding team member, will lead expansion of the company’s platform, which combines machine learning, synthetic biology, robotics, and large-scale data analysis to develop de novo therapeutic miniproteins.
Bowman previously served as Director of Protein Engineering, where he helped build the company’s discovery framework. Before joining AI Proteins, he was a postdoctoral fellow at the Institute for Protein Innovation at Boston Children’s Hospital and Harvard Medical School, where he engineered novel miniproteins for cancer therapeutics that led to multiple patents and licenses.
“Our vision is to bring miniprotein medicines to patients across many diseases. Accomplishing this requires industrializing the design-build-test process for drug discovery,” said Dr. Chris Bahl, CEO of AI Proteins. “James has been pivotal in building our protein engineering approach, and his promotion to CTO underscores both his contributions and our commitment to advancing the technology at the heart of AI Proteins.”
“I’m incredibly excited to take on the role of CTO,” said Bowman. “We built a rapid, high-throughput approach for creating miniproteins with properties and functions that we pre-define and tailor to each project’s design goals. Miniproteins offer unique advantages over existing modalities, and our platform will allow this modality to reach its full potential in medicine.”
